Analogues of muramyl dipeptide (MDP) and tuftsin limit infection and inflammation in murine model of sepsis (Q46232287)

20 December 2017

title

Analogues of muramyl dipeptide (MDP) and tuftsin limit infection and inflammation in murine model of sepsis (English)

1 reference

20 December 2017

0 references

7

Piotr Trzonkowski

1 reference

20 December 2017

2

Krystyna Dzierzbicka

1 reference

20 December 2017

Anna Wardowska

1

object named as

Anna Wardowska

1 reference

20 December 2017

author name string

Magdalena Szaryńska

3

1 reference

20 December 2017

Maria Dabrowska-Szponar

4

1 reference

20 December 2017

Katarzyna Wiśniewska

5

1 reference

20 December 2017

Andrzej Myśliwski

6

1 reference

20 December 2017

language of work or name

English

0 references

publication date

21 November 2008

1 reference

20 December 2017

published in

Vaccine

1 reference

20 December 2017

volume

27

1 reference

20 December 2017

issue

3

1 reference

20 December 2017

page(s)

369-374

1 reference

20 December 2017

New treatment strategies for severe sepsis and septic shock

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Cellular mechanisms in sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Tuftsin: on the 30-year anniversary of Victor Najjar's discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Synthesis and biological activity of tuftsin, its analogue and conjugates containing muramyl dipeptides or nor-muramyl dipeptides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Immunomodulatory properties of new conjugates of muramyl dipeptide and nor-muramyl dipeptide with retro-tuftsin (Arg-Pro-Lys-Thr-OMe).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Bench-to-bedside review: understanding genetic predisposition to sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Mechanisms of mortality in early and late sepsis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Determining the degree of immunodysregulation in sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Therapeutic intervention and targets for sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Impact of bile duct obstruction on hepatic E. coli infection: role of IL-10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Severe bacteremia results in a loss of hepatic bacterial clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Role of T cells in a murine model of Escherichia coli sepsis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Induction and protective role of antibodies in Legionella pneumophila infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

Lipopolysaccharide-binding and neutralizing activities of surfactin C in experimental models of septic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.017

10.1016/J.VACCINE.2008.11.017

7 January 2021

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

19027810

1 reference

20 December 2017